Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories.
To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
----------------------------------------------
** BREAST CANCER News **
Zoledronic Acid (ZometaR) On Top Of Endocrine Therapy Boosts Survival In Premenopausal Breast Cancer Patients
http://www.medicalnewstoday.com/articles/121669.php
The addition of zoledronic acid (ZometaR) to adjuvant endocrine therapy in premenopausal women with early breast cancer significantly reduces the risk of disease-free and recurrence-free survival events by about a third, according to results released at the 33rd Annual Congress of the European Society of Medical Oncology (ESMO.
Survival In Early Breast Cancer Improved By Adding Taxotere To Chemotherapy Regimen
http://www.medicalnewstoday.com/articles/121544.php
For patients with early stage breast cancer that has spread to the lymph nodes, adding four cycles of docetaxel (Taxotere) into a sequential regimen of epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) reduces the risk of recurrence and death, updated long-term results show.
Pegylated Liposomal Doxorubicin Beneficial In Metastatic Breast Cancer
http://www.medicalnewstoday.com/articles/121521.php
For women with metastatic breast cancer, treatment with an encapsulated form of the drug doxorubicin offers a well-tolerated option for maintenance therapy that delays progression and offers benefits in terms of survival, new results show.
Avon Cosmetics Recruits New Doctors To Breast Cancer Crusade
http://www.medicalnewstoday.com/articles/121488.php
Cosmetics giant Avon is sponsoring two doctors to carry out vital breast cancer research at the internationally renowned Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research in London, as part of Avon's ongoing commitment to tackling the disease.
----------------------------------------------
** CANCER / ONCOLOGY News **
RAD001 Shows Promise In Renal Cell Cancer Patients Who Have Failed Targeted Therapies
http://www.medicalnewstoday.com/articles/121670.php
The investigational once-daily oral mammalian target of rapamycin (mTOR) inhibitor RAD001 (with the proposed brand name Afinitor), formerly known as RAD001, significantly prolongs disease-free survival in patients with metastatic renal cell cancer who have stopped responding to targeted therapy, investigators reported here at the 33rd Annual Congress of the European Society of Medical Oncology (ESMO).
Study Of Yondelis(R) In Ovarian Cancer Shows Significant Prolongation In Progression Free Survival
http://www.medicalnewstoday.com/articles/121619.php
Positive final results of the Phase III randomized pivotal study of Yondelis® in ovarian cancer were presented during the Presidential Symposium at the ESMO congress in Stockholm. ESMO selects clinical studies that may result in a change in the current standard of care for presentation at the 2008 Presidential Symposium.
First Cancer Patients In Switzerland Treated Using RapidArc™ Technology From Varian Medical Systems
http://www.medicalnewstoday.com/articles/121596.php
Doctors in Switzerland have carried out the country's first clinical treatments using RapidArc™ technology from Varian Medical Systems. Professor Franco Cavalli, president of the UICC (International Union Against Cancer), symbolically pushed the 'beam-on' button to mark the occasion as the first of two anal canal cancer patients became the first person in the country to benefit from this advanced form of intensity-modulated radiotherapy (IMRT).
Pazopanib Shows Encouraging Activity In Several Tumour Types, Including Soft Tissue Sarcoma And Ovarian Cancer
http://www.medicalnewstoday.com/articles/121577.php
GlaxoSmithKline (GSK) has announced new data in various cancers for its investigational angiogenesis inhibitor pazopanib. Key trials in soft tissue sarcoma (STS), [1] epithelial ovarian cancer, [2] and non small cell lung cancer [3] demonstrate the potential of pazopanib across multiple tumour types.
New Data On Melanoma Treatment
http://www.medicalnewstoday.com/articles/121572.php
People who carry a particular genetic variant are at significantly increased risk of developing malignant melanoma, new research shows.Melanomas are known to be caused by exposure to the ultraviolet light in sunlight, but the precise mechanisms involved are complex.
Nanomedical Approach Targets Multiple Cancer Genes, Shrinks Tumors More Effectively
http://www.medicalnewstoday.com/articles/121567.php
Nanoparticles filled with a drug that targets two genes that trigger melanoma could offer a potential cure for this deadly disease, according to cancer researchers. The treatment, administered through an ultrasound device, demonstrates a safer and more effective way of targeting cancer-causing genes in cancer cells without harming normal tissue.
Ipilimumab Shows Benefit In Both Treatment - Naïve And Previously Treated Advanced Melanoma
http://www.medicalnewstoday.com/articles/121561.php
The investigational agent ipilimumab is showing promise as a therapy for both treatment-naïve and previously treated patients with late-stage melanoma, according to phase 2 results released here at the <a href="http://www.
The First And Only Patch For Preventing Nausea And Vomiting In Cancer Patients Undergoing Chemotherapy
http://www.medicalnewstoday.com/articles/121540.php
ProStrakan Group plc (LSE: PSK) has announced the U.S. Food and Drug Administration (F.D.A) approval of SANCUSO® (Granisetron Transdermal System), the first and only patch to provide up to five consecutive days of control of nausea and vomiting for patients receiving a moderately and/or highly nausea-inducing chemotherapy regimen.
Intravenous Iron Improves Treatment Response In Cancer Related Anemia
http://www.medicalnewstoday.com/articles/121525.php
For patients with chemotherapy-induced anemia, adding intravenous iron to treatment with the drug darbepoetin alfa results in a faster and more potent improvement in response with lower doses of the drug, according to data presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.
Investigational Drug Shows Promise In Ovarian Cancer
http://www.medicalnewstoday.com/articles/121524.php
An investigational drug that combats ovarian cancer by inhibiting the formation of new blood vessels has shown promise in a phase II trial, according to a presentation at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.
European Disparities In Access To Cancer Drugs
http://www.medicalnewstoday.com/articles/121520.php
New research has highlighted stark disparities in access to the latest cancer drugs across European Union nations, according to data presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.
Nottingham Scientists Identify Childhood Brain Cancer Genes
http://www.medicalnewstoday.com/articles/121518.php
Scientists at The University of Nottingham have isolated three important genes involved in the development of a type of childhood brain cancer. The breakthrough is revealed in a study published in the British Journal of Cancer.
Promising New Treatment Option For Women With Recurrent Ovarian Cancer
http://www.medicalnewstoday.com/articles/121514.php
Combining the new drug trabectedin with pegylated liposomal doxorubicin provides clinical benefit to women with relapsed ovarian cancer, according to new results presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.
Evident™ Microwave Ablation System Offers Surgical Oncologists And Surgical Radiologists Fast, Efficient Tool To Ablate Soft Tissue
http://www.medicalnewstoday.com/articles/121508.php
Physicians now have a powerful new tool with industry-leading technology to ablate soft tissue. The Interventional Oncology business unit of Covidien Ltd. (NYSE: COV, BSX: COV), the world leader in advanced energy-based surgical systems, today announced the global release of the Evident™ microwave ablation system.
Unibioscreen And Drais Pharmaceuticals Partner To Develop And Commercialize Unbs5162 For Treatment Of Cancer
http://www.medicalnewstoday.com/articles/121494.php
Drais Pharmaceuticals, Inc. and Unibioscreen S.A. announced that they have entered into a global agreement to develop and commercialize UNBS5162, one of Unibioscreen's investigational drug and potential breakthrough treatments for cancer.
Updated Survival Data From Three Phase II Ipilimumab Studies Showed Almost Half Of Previously Treated Metastatic Melanoma Patients Alive Beyond 1 Year
http://www.medicalnewstoday.com/articles/121489.php
Bristol-Myers Squibb Company (NYSE: BMY) announced updated survival data from three Phase II studies of ipilimumab in patients with advanced metastatic melanoma (Stage III or IV), who had previously been treated.
Comprehensive Lifestyle Changes Improve Levels Of Enzyme Telomerase Involved In Cell Ageing
http://www.medicalnewstoday.com/articles/121479.php
A pilot study has revealed for the first time that comprehensive lifestyle changes increase the levels of the enzyme telomerase, vital for maintenance of the telomeres in cells that control cell ageing.
----------------------------------------------
** CERVICAL CANCER / HPV VACCINE News **
FDA Expands Use Of HPV Vaccine Gardasil For Vaginal, Vulvar Cancer Prevention
http://www.medicalnewstoday.com/articles/121591.php
<BR />FDA on Friday approved expanding the use of Merck's human papillomavirus vaccine Gardasil to protect against cancers of the vagina and vulva, the <A href="http://www.msnbc.msn.com/id/26681058/" target=_new>AP/MSNBC.
----------------------------------------------
** COLORECTAL CANCER News **
'One-Hit' Event Provides New Opportunity For Colon Cancer Prevention, Say Fox Chase Researchers
http://www.medicalnewstoday.com/articles/121550.php
More than 30 years ago, Alfred Knudson Jr., M.D., Ph.D., revolutionized the field of cancer genetics by showing that a person must lose both their paternal and maternal copies of a particular class of cancer-inhibiting genes, called tumor-suppressor genes, in order to develop cancer.
----------------------------------------------
** LUNG CANCER News **
For The Early Detection Of Lung Cancer: An 'HIV-Test' Equivalent
http://www.medicalnewstoday.com/articles/121645.php
A team of researchers led by Fred Hutchinson Cancer Research Center reports online in the <i>Journal of Clinical Oncology</i> the validation of a potential "HIV-test" equivalent for the early detection of lung cancer.
In Non-Small-Cell Lung Cancer, Significant Benefits From Customizing Erlotinib Treatment
http://www.medicalnewstoday.com/articles/121545.php
Lung cancer patients whose tumors carry specific genetic mutations can achieve significantly longer survival when treated with targeted therapies such as erlotinib, Spanish researchers report.
Study Establishes Role For Gefitinib In Asian Non Smokers With Lung Cancer
http://www.medicalnewstoday.com/articles/121515.php
The targeted therapy gefitinib should be considered a first-line therapy for non-smoking Asian patients with adenocarcinoma of the lung, one of the most common types of lung cancer, suggests a presentation at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.
----------------------------------------------
** LYMPHOMA / LEUKEMIA News **
Unibioscreen And Drais Pharmaceuticals Partner To Develop And Commercialize Unbs5162 For Treatment Of Cancer
http://www.medicalnewstoday.com/articles/121494.php
Drais Pharmaceuticals, Inc. and Unibioscreen S.A. announced that they have entered into a global agreement to develop and commercialize UNBS5162, one of Unibioscreen's investigational drug and potential breakthrough treatments for cancer.
----------------------------------------------
** PROSTATE / PROSTATE CANCER News **
New Treatment For Prostate Cancer Pioneered By Scientists
http://www.medicalnewstoday.com/articles/121635.php
Scientists at Sunnybrook Research Institute (SRI) are developing and commercializing a promising novel therapy for the treatment of prostate cancer that may offer patients a faster and more precise treatment than existing clinical alternatives, with fewer side effects.
Prostate Cancer Treatment Options Comparison Document Published
http://www.medicalnewstoday.com/articles/121622.php
A comprehensive document listing and comparing 17 mainstream treatment options for prostate cancer has been published by the Dattoli Cancer Center & Brachytherapy Research Institute in Sarasota.
Take Charge Of Your Prostate Health During September National Prostate Health Month
http://www.medicalnewstoday.com/articles/121510.php
One in six men will be diagnosed with prostate cancer in his lifetime. 27,000 men will die from prostate cancer this year alone. Prostate cancer is a serious health issue and Americans are taking note.
-------------------------------------------------------------
You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
No comments:
Post a Comment